OPT 4.04% 47.5¢ opthea limited

While the phase III trial success rate for drugs who have...

  1. 489 Posts.
    lightbulb Created with Sketch. 72
    While the phase III trial success rate for drugs who have successfully completed phase II is overall above 50% it varies depending on the therapeutic field. Eg for oncology drugs it is only around 35% whereas for ophthalmic drugs it is almost 75%! With respect to the Carlyle group they report a success rate of 86% for the phase III trial companies they’ve invested in.
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.